Allogene Therapeutics (ALLO) Plunges 9.40% to Record Low

Allogene Therapeutics (ALLO) shares plummeted to a record low today, with an intraday decline of 9.40%.

The strategy of buying ALLO shares after they reached a recent low and holding for 1 week yielded moderate returns over the past 5 years, with a 28.70% increase in the total portfolio value. This indicates that this strategy can be effective for capturing short-term rebounds in the stock price of ALLO.

Allogene Therapeutics reported a net loss of $59.7 million for the first quarter of 2025, translating to a loss of $0.28 per share. This financial performance is likely to impact investor sentiment and stock price.

The company is set to announce its quarterly earnings on May 13, 2025. Analysts estimate an EPS of $-0.27, and investors are hoping for positive guidance and possibly surpassing these estimates, which can heavily influence stock prices.

Shares of Allogene Therapeutics were trading at $1.16 as of May 9, 2025, with a 59.8% decline over the last 52-week period. This negative return may affect investor outlook and stock dynamics heading into the earnings release.